Brief: Abvc Collaboration With Oncox Biopharma, Abvc Expecting Aggregate Income Of $13.75 Million And Royalties Of Up To $12.50 Million
09/05/2024 16:09
May 9 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA INC - COLLABORATION BETWEEN ABVC AND ONCOX
BIOPHARMA, ABVC EXPECTING AGGREGATE INCOME OF $13.75 MILLION AND
ROYALTIES OF UP TO $12.50 MILLION
* ABVC BIOPHARMA- GRANTS ONCOX EXCLUSIVE RIGHTS FOR ONE OF
ABVC’S
FOUR PRODUCTS IN ITS ONCOLOGY PIPELINE TO DEVELOP, MANUFACTURE,
COMMERCIALIZE BLEX 404
Source text for Eikon: ID:n0001213900-24-041053
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner